Angle PLC Announces Parsortix Outperforms Standard for DTC Harvest

PARSORTIX SYSTEM OUTPERFORMS CURRENT LABORATORY STANDARD FOR DISSEMINATED TUMOUR CELL HARVEST
DTCs linked to cancer relapse even after prolonged remission
DTCs harvested by the Parsortix system were 'abundant and viable' facilitating biomarker assessment

GUILDFORD, SURREY / ACCESSWIRE / October 3, 2023 / ANGLE plc (AIM:AG)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, today announces the publication of a study of disseminated tumour cells (DTCs) in bone marrow from breast cancer patients published in the International Journal of Molecular Sciences.

Researchers at the University of Tübingen, Germany, used the Parsortix^® system for the isolation and harvest of DTCs from bone marrow samples in 360 breast cancer patients (clinical stages I-IV) and compared results to the standard density centrifugation method for DTC detection. The study found that the Parsortix system was easier to use and yielded significantly higher numbers of DTCs for further analysis, compared to the standard method for DTC detection. The isolated DTCs were abundant and viable (alive and undamaged), which cannot be achieved with the standard method. This provides more and new analysis options for DTC characterisation including assessment of biomarker status which is important for targeted treatment selection and prognostic assessment.

DTCs are circulating tumour cells (CTCs) that have left the primary tumour and travelled in the blood to a distant organ, in this instance bone marrow, where they can remain dormant before being released at a later date. Release of these cells into the blood, is thought to be the most likely cause of relapse for patients who have had a prolonged remission.

One-third of breast cancer patients have DTCs already present in the bone marrow at the time of diagnosis; these patients, as well as patients with persistent DTCs, have significantly worse clinical outcomes than DTC-negative patients. Since DTC biomarker status may differ from the primary tumour with regard to key proliferation and growth receptors such as ER and HER2, the ability to evaluate these markers on DTCs may enable clinicians to optimise targeted therapy and reduce the risk of relapse.

ANGLE Chief Scientific Officer, Karen Miller, commented:

"We are pleased to share the peer-reviewed publication by the University of Tübingen that demonstrates consistently high performance of the Parsortix system for the harvest of DTCs as opposed to CTCs. This is the second study centre to demonstrate successful enrichment and harvest of DTCs from bone marrow aspirate highlighting a range of additional potential uses of the Parsortix system in clinical practice."

The research has been published as a peer-reviewed publication in the International Journal of Molecular Sciences and is available online at https://angleplc.com/publications/.

For further information:

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

For Research Use Only. Not for use in diagnostic procedures.

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix^® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix^® system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratories in the UK and the United States. Services include custom made assay development and clinical trial testing for pharma.

Over 80 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc